<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01419691</url>
  </required_header>
  <id_info>
    <org_study_id>12838</org_study_id>
    <secondary_id>Hem-2011-05-01</secondary_id>
    <nct_id>NCT01419691</nct_id>
  </id_info>
  <brief_title>Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <official_title>A Phase I Phase II Two-Step Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)/ Prolymphocytic Lymphoma (PLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kansas Bioscience Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Therapeutics for Rare and Neglected Diseases (TRND)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat
      patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or
      prolymphocytic lymphoma (PLL).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>type, incidence, severity, seriousness and relationship to auranofin of adverse events and any laboratory abnormalities</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>Leukemia, Prolymphocytic</condition>
  <arm_group>
    <arm_group_label>Phase 2 Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Auranofin 6 mg orally in the morning / 6 mg orally in the evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>auranofin</intervention_name>
    <description>6 mg twice a day for a total of 12 mg total daily dose</description>
    <arm_group_label>Phase 2 Dose</arm_group_label>
    <other_name>Ridaura</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed B-cell chronic lymphocytic leukemia (CLL), small lymphocytic
             lymphoma (SLL), prolymphocytic leukemia arising from CLL/SLL or Richter's
             transformation according to WHO criteria who require therapy based on the 2008 revised
             IWCLL criteria.

          -  Relapsed or refractory disease after receiving at least 1 prior therapy for CLL

          -  At least 18 years old; ECOG status of 1 or less; life expectancy 2 months or greater

          -  Adequate organ and marrow function (total bilirubin less than 1.5x IULN; ALT less than
             2x IULN; serum creatinine less than 1.5x ULN)

        Exclusion Criteria:

          -  have had chemotherapy, radiotherapy or immunotherapy within 4 weeks prior to entering
             study

          -  have not recovered from AEs due to agents administered more than 4 weeks prior

          -  receiving any other investigational agent

          -  known second malignancy that limits survival to less than 2 years

          -  known HIV positive

          -  uncontrolled intercurrent illness

          -  pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suman Kambhampati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2011</study_first_submitted>
  <study_first_submitted_qc>August 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2011</study_first_posted>
  <last_update_submitted>January 15, 2016</last_update_submitted>
  <last_update_submitted_qc>January 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>auranofin</keyword>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>relapsed</keyword>
  <keyword>refractory</keyword>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <keyword>PLL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Auranofin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

